Glucagonoma of the pancreas: diagnostic approach and therapeutic algorithm for a rare nosological entity.

Glucagonoma Syndrome With Necrolytic Migratory Erythema.

Shift in secretory profile of a pNET: from indolent glucagonoma to aggressive insulinoma - a case report.

Necrolytic Migratory Erythema as the First Manifestation of Functional Conversion in a Glucagonoma: A Case Report.

[The 514th case: urinary stone excretion, elevated blood glucose, pancreatic mass,and co-secretion of multiple hormones].

Study on Autophagy Death of Alpha TC1 Clone 6 (αTC1-6) Cells Induced by Trametenolic Acid Through PI3K/AKT Pathway.

Diagnosis and Management of Functional Pancreatic Neuroendocrine Tumors in Children-A Systematic Review.

Diagnostic characteristics, treatment outcomes, and prognostic factors in glucagonomas.

A unique case of glucagonoma with atypical necrolytic migratory erythema.

Premortem diagnosis of a pancreatic neuroendocrine tumour (glucagonoma) in a captive North American river otter (Lontra canadensis).

Nutritional Management of Functioning GEP-NENs.

A Case Report of Necrolytic Migratory Erythema Associated with Glucagonoma.

Glucagonoma and Glucagonoma Syndrome: An Updated Review.

Necrolytic migratory erythema with a pancreatic glucagonoma.

Familial Mahvash disease with metastatic pancreatic NET and MEN1 mutations.

Functioning neuroendocrine tumors (NET): Minimum requirements for a NET specialist.

Clinical Relevance of ATRX/DAXX Gene Mutations and ALT in Functioning Pancreatic Neuroendocrine Tumors.

Case report: Anesthesia management for surgical treatment of glucagonoma with symptom of characterized necrolytic migratory erythema.

Necrolytic migratory erythema: a fortuitous diagnosis.

Glucagon-Producing Pancreatic Neuroendocrine Tumors (Glucagonomas) are Enriched in Aggressive Neoplasms with ARX and PDX1 Co-expression, DAXX/ATRX Mutations, and ALT (Alternative Lengthening of Telomeres).

Non-functional alpha-cell hyperplasia with glucagon-producing NET: a case report.

Manifestations of Endocrine Disease in the Lower Extremities: Beyond the Diabetic Foot.

Case report: Surgical treatment and literature review of a recurrent case of glucagonoma.

A nuclear beacon of hope: an advanced, metastatic glucagonoma treated with [177Lu]Lu-DOTA-TATE.

Management of functional neuroendocrine tumors.

Necrolytic migratory erythema caused by pancreatic hyperglycemia with emphasis on therapeutic and prognosis: A case report.

Characteristics, therapy, and outcome of rare functioning pancreatic neuroendocrine neoplasms.

[Glucagonoma - a rare neuroendocrine tumor (NET) that typically originates in the pancreas].

Advances in basic research on glucagon and alpha cells.

Well-differentiated G1 and G2 pancreatic neuroendocrine tumors: a meta-analysis of published expanded DNA sequencing data.

Pseudoglucagonoma Syndrome Following Frey's Surgery: A Case Report of a Rare Presentation.

Genetic disorders and insulinoma/glucagonoma.

Diagnosis and comprehensive treatment of a glucagonoma in a patient with residual intrahepatic metastases postoperatively: A case report and literature review.

A novel likely pathogenetic variant p.(Cys235Arg) of the MEN1 gene in multiple endocrine neoplasia type 1 with multifocal glucagonomas.

Characteristics and treatment options of glucagonomas: a national study from the French Group of Endocrine Tumors and ENDOCAN-RENATEN network.

Hepatic Glucagonoma in a Post-bariatric Female Patient: A Case Report.

Glucagonoma-induced Dilated Cardiomyopathy in a Young Woman.

Synchronous Insulinoma and Glucagonoma: A Review of the Literature.

Practical therapeutic approach in the management of diabetes mellitus secondary to Cushing's syndrome, acromegaly and neuroendocrine tumours.

Diabetes Mellitus Secondary to Endocrine Diseases: An Update of Diagnostic and Treatment Particularities.

European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes.

Emerging therapies for advanced insulinomas and glucagonomas.

One hundred years after the discovery of insulin and glucagon: the history of tumors and hyperplasias that hypersecrete these hormones.

Glucagon cell hyperplasia and neoplasia: a recently recognized endocrine receptor disease.

Analysis of Clinical Characteristics and Survival in Patients With Functional Neuroendocrine Tumors of Gastrointestinal Origin.

A case of multiple glucagonomas with no clinical manifestations of excess glucagon despite hyperglucagonemia.

Recurrent pruritic polymorphic lesions associated with weight loss.

An Insight on Functioning Pancreatic Neuroendocrine Neoplasms.

Circulating Neuroendocrine Tumor Biomarkers: Past, Present and Future.

Glucagonoma Syndrome: A Rare Paraneoplastic Disorder due to Neuroendocrine Tumor of the Pancreas.

Skin manifestations of neuroendocrine neoplasms: review of the literature.

[Migratory necrolytic erythema as a manifestation of pancreatic neuroendocrine tumor. Clinical-radiological evaluation].

Necrolytic migratory erythema is an important visual cutaneous clue of glucagonoma.

Case report of a recurrent resected glucagonoma.

A Glucagonoma Presenting as Cerebral Vein Thrombosis and Diabetes.

How Many Times Can One Go Back to the Drawing Board before the Accurate Diagnosis and Surgical Treatment of Glucagonoma?

Case of delayed diagnosis of necrolytic migratory erythema.

[Necrolytic migratory erythema in a patient with a glucagonoma].

Bilateral Vestibular Failure May Improve With Treatment of the Underlying Condition: A Report of 2 Cases.

Glucagonoma syndrome with necrolytic migratory erythema as initial manifestation.

Necrolytic migratory erythema-like eruption and paradoxical psoriasis associated with adalimumab treatment.

Distinctive detection of insulinoma using [18F]FB(ePEG12)12-exendin-4 PET/CT.

A germline c.1546dupC MEN1 mutation in an MEN1 family: A case report.

Glucagonoma with diffuse enlargement of pancreas mimicking autoimmune pancreatitis diagnosed by EUS-guided FNA.

Treatment of Glucagonoma-Related Necrolytic Migratory Erythema With Peptide Receptor Radionuclide Therapy.

[Neuroendorine paraneoplastic syndromes].

Pancreatoduodenectomy for Neuroendocrine Tumors in Patients with Multiple Endocrine Neoplasia Type 1: An AFCE (Association Francophone de Chirurgie Endocrinienne) and GTE (Groupe d'étude des Tumeurs Endocrines) Study.

Pancreatic neuroendocrine neoplasms: Clinicopathological features and pathological staging.

Clinical Characteristics and Management of Functional Pancreatic Neuroendocrine Neoplasms: A Single Institution 20-Year Experience with 286 Patients.

Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes.

Benign-Appearing Glucagonoma Undergoing Malignant Transformation after a Prolonged Period.

Concomitant Insulinoma and Glucagonoma in Solitary Cystic Pancreatic Lesion in a Young Male Patient.

Glucagonoma: From skin lesions to the neuroendocrine component (Review).

The RNA-binding protein, HuD regulates proglucagon biosynthesis in pancreatic α cells.

Necrolytic Migratory Erythema Associated with a Glucagonoma.

Necrolytic migratory erythema: an important sign of glucagonoma.

MANIFESTATIONS OF GLUCAGONOMA SYNDROME.

The magnesium transporter NIPAL1 is a pancreatic islet-expressed protein that conditionally impacts insulin secretion.

Pseudoglucagonoma syndrome: Description of an 'Idiopatic' case.

Necrolytic Acral Erythema: Current Insights.

Neuropsychiatric symptoms, skin disease, and weight loss: necrolytic migratory erythema and a glucagonoma.

Proof of concept for stereotactic body radiation therapy in the treatment of functional neuroendocrine neoplasms.

A retrospective comparison of robotic versus laparoscopic distal resection and enucleation for potentially benign pancreatic neoplasms.

[Facial edema and erythroderma in a 54 year-old woman].

Application of Somatostatin, Chemotherapy Combined with TAE in Heterogeneous Glucagonoma Presented with Necrolytic Migratory Erythema.

Occult insulinoma, glucagonoma and pancreatic endocrine pseudotumour in a patient with multiple endocrine neoplasia type 1.

Case of autoimmune progesterone dermatitis presenting as necrotic migratory erythema successfully controlled by danazol.

Diarrhea: a missed D in the 4D glucagonoma syndrome.

Molecular imaging of a glucagonoma with 18F-FDG PET/CT and 68Ga-DOTATATE PET/CT imaging: A case report and review of the literature.

Unremitting chronic skin lesions: a case of delayed diagnosis of glucagonoma.

Spleen-preserving distal pancreatectomy and lymphadenectomy for glucagonoma syndrome: A case report.

Glucagonoma syndrome with severe erythematous rash: A rare case report.

Glucagonoma-related necrolytic migratory erythema.

Systemic and Autoimmune Diseases.

Resolution of necrolytic migratory erythema with somatostatin analogue in a patient diagnosed with pancreatic glucagonoma.

Glucagonoma syndrome with atypical necrolytic migratory erythema.

Glucagonoma with Paraneoplasic Dermatitis: Diagnosis and Management.

PARP-14 Promotes Survival of Mammalian α but Not β Pancreatic Cells Following Cytokine Treatment.

Clinicopathological characteristics and risk factors for recurrence of well-differentiated pancreatic neuroendocrine tumors after radical surgery: a case-control study.

Pancreatic Ductal Adenocarcinoma Derived From an Intraductal Papillary Neoplasm With Synchronous Incidental Glucagonoma: A Case Report and Literature Review.

[Necrolytic migratory erythema revealing glucagonoma syndrome].

Necrolytic migratory erythema.

Glucagonoma-associated dilated cardiomyopathy refractory to somatostatin analogue therapy.

Imaging of Pancreatic-Neuroendocrine Tumours: An Outline of Conventional Radiological Techniques.

Necrolytic Migratory Erythema: Complete Healing after Surgical Removal of Pancreatic Carcinoma.

Glucagonoma and Glucagonoma Syndrome: One Center's Experience of Six Cases.

Metabolic effects of glucagon in humans.

Image Gallery: Necrolytic migratory erythema associated with glucagonoma.

Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors.

The impact of failure to achieve symptom control after resection of functional neuroendocrine tumors: An 8-institution study from the US Neuroendocrine Tumor Study Group.

Glucagonoma-Associated Necrolytic Migratory Erythema: The Broad Spectrum of the Clinical and Histopathological Findings and Clues to the Diagnosis.

Peptidomic analysis of endogenous plasma peptides from patients with pancreatic neuroendocrine tumours.

Glucagonoma With Necrolytic Migratory Erythema: Metabolic Profile and Detection of Biallelic Inactivation of DAXX Gene.

[Surgical strategies for small sporadic neuroendocrine pancreatic tumors].

Management of functional neuroendocrine tumors of the pancreas.

A Persistent Migrating Rash.

Erythema as a Visual Surrogate Marker of Glucagonoma.

Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important.

A review of cutaneous manifestations within glucagonoma syndrome: necrolytic migratory erythema.

Imaging features of malignant abdominal neuroendocrine tumors with rare presentation.

Glucagonoma and the glucagonoma syndrome.

A Case Series of Molecular Imaging of Glucagonoma After Initial Therapy-68Ga-DOTATATE PET/CT Reveals Similar Results as in Neuroendocrine Tumors of Other Origin in Follow-up and Re-evaluation.

Normoglycemic glucagonoma syndrome associated with necrolytic migratory erythema.

Malignant transformation of glucagonoma with SPECT/CT In-111 OctreoScan features: A case report.

Psoriasiform lesions: Uncommon presentation of glucagonoma.

Glucagonoma syndrome with serous oligocystic adenoma: A rare case report.

Emergency pancreatic resection for glucagonoma associated with severe necrolytic migratory erythema.

Necrolytic Migratory Erythema: A Forgotten Paraneoplastic Condition.

Metastatic Hepatoid Carcinoma of the Pancreas: First Description of Treatment With Capecitabine and Temozolomide.

[Diabetes mellitus secondary to an endocrine pathology : when to think about it ?].

Necrolytic Acral Erythema in Seronegative Hepatitis C.

Challenging Differential Diagnosis of Hypergastremia and Hyperglucagonemia with Chronic Renal Failure: Report of a Case with Multiple Endocrine Neoplasia Type 1.

Necrolytic migratory erythema associated with glucagonoma treated successfully with cyclosporine.

Management of the hormonal syndrome of neuroendocrine tumors.

Glucagonoma-Associated Rash.

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors.

B-mode and contrast-enhancement characteristics of small nonincidental neuroendocrine pancreatic tumors.

Foxa2, a novel protein partner of the tumour suppressor menin, is deregulated in mouse and human MEN1 glucagonomas.

Glucagonoma syndrome: report of one case.

Glucagon and Amino Acids Are Linked in a Mutual Feedback Cycle: The Liver-α-Cell Axis.

Pancreatic α-cell hyperplasia and hyperglucagonemia due to a glucagon receptor splice mutation.

Imaging of secretory tumors of the gastrointestinal tract.

Operation for insulinomas in multiple endocrine neoplasia type 1: When pancreatoduodenectomy is appropriate.

Characterization of pancreatic glucagon-producing tumors and pituitary gland tumors in transgenic mice overexpressing MYCN in hGFAP-positive cells.

The biology of glucagon and the consequences of hyperglucagonemia.

Necrolytic migratory erythema and pancreatic glucagonoma.

Necrolytic migratory erythema: A diagnostic clue in glucagonoma syndrome.

Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours.

Prognostic factors in resected pancreatic neuroendocrine tumours: Experience in 95 patients.

Bone turnover response is linked to both acute and established metabolic changes in ultra-marathon runners.

Glucagonoma syndrome: a review and update on treatment.

Necrolytic migratory erythema with recalcitrant dermatitis as the only presenting symptom.

Pancreatic neuroendocrine tumors: contemporary diagnosis and management.

Over-expression of Slc30a8/ZnT8 selectively in the mouse α cell impairs glucagon release and responses to hypoglycemia.

Clinical Presentation and Diagnosis of Pancreatic Neuroendocrine Tumors.

Glucagonoma and Glucagonoma Syndrome: A Case Report with Review of Recent Advances in Management.

A short history of neuroendocrine tumours and their peptide hormones.

Do glucagonomas always produce glucagon?

Necrolytic migratory erythema associated with fatty liver disease and the psuedoglucagonoma syndrome.

Different Hormonal Expression Patterns Between Primary Pancreatic Neuroendocrine Tumors and Metastatic Sites.

Delayed diagnosis of glucagonoma syndrome: a case report.

Metastatic VIPoma presenting as an ovarian mass.

Iatrogenic Necrolytic Migratory Erythema in an Infant with Congenital Hyperinsulinism.

Glucagonoma syndrome: A case report.

Paediatric necrolytic migratory erythema as a presenting sign of glucagonoma syndrome.

Rapid Clearance of Necrolytic Migratory Erythema Following Intravenous Administration of Amino Acids.

[A case of MEN type I which complicated with glucagonoma after surgical treatment for gastrinoma in the 36th year].

Progranulin Stimulates Proliferation of Mouse Pancreatic Islet Cells and Is Overexpressed in the Endocrine Pancreatic Tissue of an MEN1 Mouse Model.

Proposed Radiation Induced Hormone Crisis in a Patient with Glucagonoma.

A Novel Missense Mutation of the MEN1 Gene in a Patient with Multiple Endocrine Neoplasia Type 1 with Glucagonoma and Obesity.

Biochemical Testing in Patients with Neuroendocrine Tumors.

Glucagonoma syndrome associated with necrolytic migratory erythema.

Glucagonoma Pancreatic Neuroendocrine Tumor Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy.

Rapid improvement of glucagonoma-related necrolytic migratory erythema with octreotide.

[Neuroendocrine well-differentiated pancreatic tumors].

Glucagon receptor gene mutations with hyperglucagonemia but without the glucagonoma syndrome.

Imaging features of glucagonoma syndrome: A case report and review of the literature.

Diagnosis of functioning pancreaticoduodenal neuroendocrine tumors.

Reversal of dilated cardiomyopathy after glucagonoma excision.